A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2020
Price : $35 *
At a glance
- Drugs Mirogabalin (Primary) ; Pregabalin
- Indications Fibromyalgia
- Focus Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 31 Aug 2017 According to a Daiichi Sankyo media release, the results from the global clinical development program consisting of several phase 3 clinical trials, including NEUCOURSE, REDUCER and ALDAY, will serve as the basis for potential regulatory submissions in various countries.
- 30 Jun 2017 According to a Daiichi Sankyo media release, full results from this trial will be disclosed in upcoming scientific mediums.
- 30 Jun 2017 Results from this trial published in a Daiichi Sankyo Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History